Scholar Rock appoints Srinivas Akkaraju to Board of Directors

Scholar Rock Holding Corp

Board expanded to nine members; Dr. Akkaraju appointed as Class I director effective July 26, 2022.
Akkaraju is founder and Managing General Partner at Samsara BioCapital, a recent investor in SRRK.
He is deemed independent under NASDAQ rules and will receive standard non-employee director compensation.
Akkaraju serves on boards of Chinook Therapeutics, Intercept Pharmaceuticals, Syros Pharmaceuticals, and others.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Srinivas Akkaraju

Director

SRRK · Scholar Rock Holding Corp

Effective: 2022-07-26
Filed: July 26, 2022, 7:59 PM ET

increased the size of the Board to nine (9) directors and subsequently appointed Srinivas Akkaraju to join the Board filling the vacancy created by the increase in the size of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Srinivas Akkaraju was appointed as Director at Scholar Rock Holding Corp.

Action: appointed
Role: Director

Exact text from the filing

increased the size of the Board to nine (9) directors and subsequently appointed Srinivas Akkaraju to join the Board filling the vacancy created by the increase in the size of the Board.

View on SEC.gov

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-082822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.